| 
				   | 
			
		| (68 intermediate revisions not shown.) | 
| Line 1: | 
Line 1: | 
| - | [[Image: Nexium.jpg|300px|right|thumb| AstraZeneca’s Nexium]]  |   | 
|   | {{#tree:id=siteTree|  |   | {{#tree:id=siteTree|  | 
|   | <big>The following is a list of major pharmaceutical compound targets, drugs, and information organized by disease. </big>   |   | <big>The following is a list of major pharmaceutical compound targets, drugs, and information organized by disease. </big>   | 
| Line 6: | 
Line 5: | 
|   |  |   |  | 
|   | **Alzheimer’s Disease  |   | **Alzheimer’s Disease  | 
| - | ***[[2ace|Acetylcholinesterase from Torpedo Californica]]  | + | ***See: [[Alzheimer's Disease]]  | 
| - | ***[[Acetylcholinesterase]]
  | + |  | 
| - | ***[[Acetylcholine]]
  | + |  | 
| - | ***[[Flexibility of aromatic residues in acetylcholinesterase|Flexibility of Aromatic Residues in AChE]]
  | + |  | 
| - | ***[[Amyloid Beta]]
  | + |  | 
| - | ***[[Acetylcholine binding protein]]  (AChBP)
  | + |  | 
| - | ***[[Butyrylcholinesterase]] (BChE)
  | + |  | 
| - | ***Drug Compounds & Substrates
  | + |  | 
| - | ****[[AChE_bivalent_inhibitors|Bivalent Inhibitors of Acetylcholinesterase]]
  | + |  | 
| - | ****[[AChE_bivalent_inhibitors_%28Part_II%29|Bivalent Inhibitors of Acetylcholinesterase, Part II]]
  | + |  | 
| - | ****[[AChE_inhibitors_and_substrates|Inhibitors and Substrates of Acetylcholinesterase]]
  | + |  | 
| - | ****[[ AChE_inhibitors_and_substrates_%28Part_II%29|Inhibitors and Substrates of Acetylcholinesterase, Part II]]
  | + |  | 
| - | ****[[ AChE_inhibitors_and_substrates_%28Part_III%29|Inhibitors and Substrates of Acetylcholinesterase, Part III]]
  | + |  | 
| - | ****Specific Examples:
  | + |  | 
| - | *****[[1eve|Aricept Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[2dfp|DFP (Aged) Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1ax9|Edrophonium Complexed with Acetylcholinesterase]] or [[2ack|Here]]
  | + |  | 
| - | *****[[2j3q|Fluorophore Thioflavin T Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1dx6|Galanthamine Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1vot|Huperzine A Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1w6r|Iminium Galanthamine Derivative bound to Acetylcholinesterase]] or [[1w4l|Here]], or [[1w76|Here]].
  | + |  | 
| - | *****[[1gqs|NAP Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1vxr|O-tthylmethylphosphonylated Acetylcholinesterase]]
  | + |  | 
| - | *****[[2wfz|Soman Complexed with Acetylcholinesterase]] or [[2wg0|Here]], or [[2wg1|Here]], or [[1cfj|Here]], or [[1som|Here]].
  | + |  | 
| - | *****[[1acj|Tacrine Complexed with Acetylcholinesterase]]
  | + |  | 
| - | **** Bivalent Inhibitors
  | + |  | 
| - | *****[[1u65|Anticancer Prodrug CPT-11 Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1eve|Aricept Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1w4l|Bis-Acting Galanthamine Derivative Complexed with Acetylcholinesterase]], or [[1w76|Here]], or [[1w6r|Here]]
  | + |  | 
| - | *****[[2cmf|Bis-Tacrine Derivative Complexed with Acetylcholinesterase]] or [[2ckm|Here]] or [[1odc|Here]]
  | + |  | 
| - | *****[[1acl|Bisquaternary Decamethonium Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1e3q|BW284C51 Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1zgb|Hupyridone Derivative Complexed with Acetylcholinesterase]], or [[1zgc|Here]], or [[1h22|Here]], or [[1h23|Here]]
  | + |  | 
| - | *****[[1ut6|N-9-(1',2',3',4'-TETRAHYDROACRIDINYL)-1,8-DIAMINOOCTANE Complexed with Acetylcholinesterase]]
  | + |  | 
| - | *****[[1jjb|PEG-SH Complexed with Acetylcholinesterase]]
  | + |  | 
| - | ***[[Gamma-Secratase]]
  | + |  | 
| - | ***Glutamate Receptor
  | + |  | 
| - | ****[[Glutamate receptor (GluA2)]]
  | + |  | 
| - | ****[[Molecular_Playground/Glutamate_Receptor|Glutamate Receptor]]
  | + |  | 
|   |  |   |  | 
|   | **Anemia  |   | **Anemia  | 
|   | ***[[Erythropoietin]]  |   | ***[[Erythropoietin]]  | 
|   | + |  | 
|   | + | **Antifungal  | 
|   | + | ***[[Noxafil]]  | 
|   | + |  | 
|   | + | **Antimalarial  | 
|   | + | ***[[Malarial Dihydrofolate Reductase as Drug Target]]  | 
|   | + |  | 
|   | + | **Anti-parasitic  | 
|   | + | ***[[Ivermectin|Drug: Ivermectin; Target: Glutamate-gated chloride channels]]  | 
|   |  |   |  | 
|   | **Asthma and other Pulmonary Disease States  |   | **Asthma and other Pulmonary Disease States  | 
| - | ***[[Beta-2-Andrenergic Receptor]]  | + | ***[[Beta-2 Adrenergic Receptor]]  | 
|   | ***[[Leukotriene Receptor]]  |   | ***[[Leukotriene Receptor]]  | 
|   |  |   |  | 
| Line 58: | 
Line 28: | 
|   |  |   |  | 
|   | **Autoimmune Diseases  |   | **Autoimmune Diseases  | 
| - | ***[[Tumor Necrosis Factor Receptor]]  | + | ***[[Prolyl Endopeptidase]]  | 
|   | + | ***[[Tumor necrosis factor receptor]]  | 
|   | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]]  |   | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]]  | 
|   |  |   |  | 
|   | **Bacterial Infections  |   | **Bacterial Infections  | 
| - | ***[[Molecular_Playground/PcrA_Helicase|PcrA Helicase]]  | + | *** See: [[Bacterial Infections]]  | 
|   | + | ***[[Treatment of Tuberculosis]]  | 
|   |  |   |  | 
|   | **Blood Clots, Haemophilia, & Thrombic Events  |   | **Blood Clots, Haemophilia, & Thrombic Events  | 
|   | ***[[P2Y12]]  |   | ***[[P2Y12]]  | 
|   | ***Haemophilia  |   | ***Haemophilia  | 
| - | ****[[Jolanta_amblo|Factor VII]]  | + | **** See: [[Hemophilia]]  | 
| - | ****[[Factor_IX|Factor IX]]
  | + | ***[[Platelet-receptor glycoprotein Ib alpha]]  | 
| - | ****[[Factor_Xa|Factor Xa]]
  | + |  | 
|   |  |   |  | 
|   | **Cancer  |   | **Cancer  | 
| - | ***Caspases  | + | *** See: [[Cancer]]  | 
| - | ****[[Molecular_Playground/Caspase-6|Caspase-6]]
  | + |  | 
| - | ****[[Molecular_Playground/Caspase-7_Dynamics|Caspase-7 Dynamics]]
  | + |  | 
| - | ****[[Molecular_Playground/Caspase-9_Regulation|Caspase-9 Regulation]]
  | + |  | 
| - | ***[[User:Greg_Black/Sandbox_1|Cisplatin Information]]
  | + |  | 
| - | ***[[Michael Purol Sandbox 1|Cyclin Dependent Kinase Inhibitor]]
  | + |  | 
| - | ***[[6-deoxyerythronolide_B_synthase_%28DEBS%29|DEBS]]
  | + |  | 
| - | ***[[Farnesoid X Receptor]]
  | + |  | 
| - | ***Growth Factors & Receptors
  | + |  | 
| - | ****Epidermal Growth Factor
  | + |  | 
| - | *****[[Epidermal Growth Factor]]
  | + |  | 
| - | *****[[Epidermal Growth Factor Receptor]]
  | + |  | 
| - | ****[[Hepatocyte Growth Factor Receptor]]
  | + |  | 
| - | ****[[Human Epidermal Growth Factor Receptor 2]]
  | + |  | 
| - | ****Insulin-Like Growth Factor
  | + |  | 
| - | *****[[Insulin-Like Growth Factor-1]]
  | + |  | 
| - | *****[[Insulin-Like Growth Factor-1 Receptor]]
  | + |  | 
| - | ****Vascular Growth Factor
  | + |  | 
| - | *****[[Vascular Endothelial Growth Factor]]
  | + |  | 
| - | *****[[Vascular Endothelial Growth Factor Receptor]]
  | + |  | 
| - | ***[[Molecular_Playground/FIH|Hypoxia Inducible Factor (HIF)]]
  | + |  | 
| - | ***[[Heat Shock Protein 90]]
  | + |  | 
| - | ***[[1ebm|Human 8-Oxoguanine Glycosylase Structure and Mechanism (HOGG1)]]
  | + |  | 
| - | ***Kinases
  | + |  | 
| - | ****[[Cory_Tiedeman_sandbox|Cyclin Dependent Kinase-4]]
  | + |  | 
| - | ****[[Cell Division Cycle 7-Related Protein Kinase]]
  | + |  | 
| - | ****[[Mammalian Target of Rapamycin]]
  | + |  | 
| - | ****Mitogen-Activated Proteins
  | + |  | 
| - | *****Mitogen-Activated Protein Kinase
  | + |  | 
| - | *****Mitogen-Activated Protein Kinase Kinase
  | + |  | 
| - | *****Mitogen-Activated Protein Kinase Kinase Kinase
  | + |  | 
| - | ******[[c-Raf]]
  | + |  | 
| - | ****[[Phosphatidylinositol 3-Kinase]]
  | + |  | 
| - | ****[[SRC]]
  | + |  | 
| - | ***[[Matt Routh sandbox|MDM2 Bound to p53]]
  | + |  | 
| - | ***[[P-glycoprotein:_Why_Cancer_Drugs_Fail|P-Glycoprotein: Why Cancer Drugs Fail]]
  | + |  | 
| - | ***[[p53]]
  | + |  | 
| - | ***[[Ann_Taylor_sandbox_Proteins_in_Cancer|Proteins in Cancer]]
  | + |  | 
| - | ***[[Chad Sorenson sandbox 1|Retinoblastoma Protein]]
  | + |  | 
| - | ***[[Molecular_Playground/Taxol|Taxol Information]]
  | + |  | 
| - | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]]
  | + |  | 
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
  | + |  | 
|   |  |   |  | 
|   | **Compromised Immune System  |   | **Compromised Immune System  | 
|   | ***[[Granulocyte-macrophage colony-stimulating factor]]  |   | ***[[Granulocyte-macrophage colony-stimulating factor]]  | 
|   |  |   |  | 
| - | **Delivery Systems  | + | **Delivery Systems & Biotech  | 
|   | ***[[Molecular_Playground/Targeting_Peptide|Targeted Drug Delivery]]  |   | ***[[Molecular_Playground/Targeting_Peptide|Targeted Drug Delivery]]  | 
|   | + | ***[[Monoclonal Antibody]]  | 
|   |  |   |  | 
|   | **Diabetes & Hypoglycemia  |   | **Diabetes & Hypoglycemia  | 
| - | ***[[Molecular_Playground/Insulin|Insulin Information]]  | + | *** See: [[Diabetes]]  | 
| - | ***[[User:Mary Ball/Leptin|Leptin]]
  | + |  | 
| - | ***[[Peroxisome Proliferator-Activated Receptors]]
  | + |  | 
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
  | + |  | 
|   |  |   |  | 
|   | **Digestive Diseases  |   | **Digestive Diseases  | 
| - | ***[[Proton Pump]]  | + | ***Proton Pump  | 
|   | + | ****[[Esomeprazole and H+/K+ - ATPase Interaction]]  | 
|   |  |   |  | 
|   | **Erectile Dysfunction  |   | **Erectile Dysfunction  | 
| Line 134: | 
Line 63: | 
|   |  |   |  | 
|   | **Hypertension & Congestive Heart Failure  |   | **Hypertension & Congestive Heart Failure  | 
| - | ***[[Angiotensin-Converting Enzyme]]  | + | ***See: [[Hypertension & Congestive Heart Failure]]  | 
| - | ***[[Calcium Channel]]
  | + |  | 
|   |  |   |  | 
|   | **Inflammation & Rheumatoid Arthritis  |   | **Inflammation & Rheumatoid Arthritis  | 
| - | ***[[Cyclooxygenase]]  | + | ***[[Inflammation & Rheumatoid Arthritis]]  | 
| - | ***[[Aspirin effects on COX aka PGHS|Asprin Effects on Cyclooxygenase]]
  | + |  | 
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
  | + |  | 
|   |  |   |  | 
|   | **Metabolic Disorders  |   | **Metabolic Disorders  | 
| - | ***[[Acid-beta-glucosidase]]  | + | *** See: [[Metabolic Disorders]]  | 
| - | ***[[Molecular_playground/beta_2_microglobulin|ß-2 Microglobulin]]
  | + |  | 
| - | ***[[Molecular_Playground/Human_PPCA|Protective Protein/Cathepsin A (PPCA)]]
  | + |  | 
| - | ***[[Molecular_Playground/Human_Protective_Protein_Cathepsin_A|Protective Protein/Cathepsin A (PPCA) 2]]
  | + |  | 
| - | ***[[Treatment_of_Gaucher_disease]]
  | + |  | 
| - | ***[[Molecular_Playground/Velaglucerase|Velaglucerase]]
  | + |  | 
|   |  |   |  | 
| - | **Schizophrenia, Bipolar Depression, Insomnia, and Anxiety Disorders  | + | **Schizophrenia, Bipolar Depression, Depression, Insomnia, and Anxiety Disorders  | 
| - | ***[[Dopamine Receptor]]  | + | ***[[Dopamine receptor]]  | 
| - | ***[[Andrenergic Receptor]]  | + | ***[[Adrenergic receptor]]  | 
| - | ***[[Histamine Receptor]]  | + | ***[[Histamine H1 receptor]]  | 
| - | ***[[Opioid Receptor]]  | + | ***[[Opioid receptor]]  | 
|   | + | ***[[5-hydroxytryptamine receptor]]  | 
|   |  |   |  | 
|   | **Viral Infection  |   | **Viral Infection  | 
| - | ***[[Molecular_Playground/T7_RNA_Polymerase_%287_mer_int%29|T7 RNA Polymerase]]  | + | ***[[Molecular_Playground/T7_RNA_Polymerase_%287_mer_int%29| T7 RNA Polymerase]]  | 
| - | ***HIV  | + | *** HIV  | 
| - | ****[[HIV-1 protease|HIV-1 Protease]]  | + | **** See: [[Human Immunodeficiency Virus]]  | 
| - | ****[[User:Tsung-Yi_Lin/Sandbox|HIV-1 Protease Analysis]]
  | + | *** Influenza  | 
| - | ****[[HIV-1 Gag]]
  | + | **** See: [[Influenza]]  | 
| - | ****[[HIV-1 Gag Recruitment of Tsg101 and the Viral Budding Process]]  | + | *** [[Herpes Simplex Virus Thymidine Kinase]]  | 
| - | ****[[User:Eric Martz/Molecular Playground/HIVDrug|HIV Drug]]  | + | *** [[NS5B|RNA Dependent RNA Polymerase from Hepatitis C Virus]]  | 
| - | ****[[Molecular_Playground/HIV_Protease_Inhibitor|HIV Protease Inhibitor]]
  | + | *** Poliovirus  | 
| - | ****[[HIV-1_Subtype_C_Protease|HIV-1 Subtype C Protease]]
  | + | ****[[Journal:PLoS ONE:1|Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates]]  | 
| - | ****[[Reverse Transcriptase]]
  | + | *** [[Interferon]]  | 
| - | ***Influenza
  | + |  | 
| - | **** [[Avian Influenza Neuraminidase, Tamiflu and Relenza]]
  | + |  | 
| - | **** [[Avian Influenza Neuraminidase, Tamiflu and Relenza]]
  | + |  | 
| - | ****H1N1 Sequence Analyses
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1|H1N1 Swine Flu Sequence Analysis]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/MP1/MSA|H1N1 Swine Flu Multiple Sequence Alignment]]  | + |  | 
| - | ****** [[User:Michael Strong/H1N1/MP2/MSA|H1N1 Sequence Alignment of MP2 Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/PB2|H1N1 Sequence Alignment of PB2 Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/PB1|H1N1 Sequence Alignment of PB1 Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/NS2/MSA|H1N1 Sequence Alignment of NS2 Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/PA|H1N1 Sequence Alignment of PA Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/HA|H1N1 Sequence Alignment of HA Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/NP|H1N1 Sequence Alignment of NP Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/NA|H1N1 Sequence Alignment of NA Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/MP|H1N1 Sequence Alignment of MP Protein]]
  | + |  | 
| - | ****** [[User:Michael_Strong/H1N1/NS|H1N1 Sequence Alignment of NS Protein]]
  | + |  | 
| - | **** [[Influenza hemagglutinin]]
  | + |  | 
| - | **** [[Molecular_Playground/Influenza_A_M2_transmembrane_domain|Influenza A M2 Transmembrane Domain]]
  | + |  | 
| - | **** [[Proton Channels]] featuring a morph of the M2 proton channel of influenza.
  | + |  | 
| - | **** [[Molecular Playground/Tamiflu|Tamiflu]]
  | + |  | 
| - | **** [[Molecular Playground/Relenza|Relenza]]
  | + |  | 
|   | }}  |   | }}  | 
|   | + |  | 
|   | + | See [[Pharmaceutical Drugs]] for descriptions and analysis of well known drugs  |